{"paper_id":"1b20c490-c74c-4636-9898-f0da20faedac","body_text":"According to the Health Insurance Review and Assessment Service-National Health Insurance Service of South Korea, the prevalence of obesity among women aged >20 years will increase by 27.8% by 2021, continuing the decade-long rise. The number of women treated for infertility in Korea is expected to increase from 121,038 in 2018–140,458 in 2022. A recent study revealed that female infertility in Korea was associated with obesity, with an odds ratio of 2.06 (95% confidence interval, 1.61–2.64) compared to women with a normal body mass index (BMI) (18.5 kg/m 2  ≤ BMI < 25 kg/m 2 ) [ 1 ]. Since South Korea has the lowest total fertility rate (0.78) among the Organization for Economic Co-operation and Development countries, the rising prevalence of obesity among reproductive-aged women, along with increasing infertility rates, poses a significant social challenge.\nIn 2021, the American Society for Reproductive Medicine outlined the adverse effects of obesity on reproduction, including impaired ovulatory function, decreased responsiveness to ovarian stimulation, diminished oocyte quality, lower fertilization rates, increased miscarriage rates, and increased risks of maternal and fetal complications during pregnancy [ 2 ]. These findings align with those of other studies [ 1 , 3 – 6 ]. However, obesity has not been reported to significantly affect the clinical or embryological outcomes of  in vitro  fertilization (IVF) [ 7 – 8 ].\nDespite the numerous studies on infertility and obesity, the underlying mechanisms remain unclear. Yong et al. reported that obesity affects the hypothalamic-pituitary-ovarian axis, oocyte maturation, embryonic development, and all stages of fetal development, leading to decreased female reproduction [ 9 ]. Lipotoxicity is the primary mechanism underlying this impairment, which causes mitochondrial damage in oocytes, an increase in reactive oxygen species, and endoplasmic reticulum stress. These conditions ultimately disrupt hormone production, the formation of cumulus-oocyte complexes (COC), fertilization, and embryonic development [ 10 – 15 ]. Furthermore, obesity causes chronic inflammation by increasing proinflammatory cytokine levels and gene activity [ 16 – 18 ].\nAs the follicular fluid (FF) represents the immediate microenvironment of the COC, its analysis provides insights into the effects of obesity on IVF outcomes. Alterations in the FF components can reflect in the metabolic levels and influence oocyte development, maturation, and embryo quality [ 19 – 21 ]. Lipid metabolism is essential for oocyte meiosis and folliculogenesis. It provides energy through β-oxidation in mitochondria and functions both as a mediator for cell signaling and as a structural component of cellular membranes and steroid synthesis [ 15 , 22 – 24 ]. Previous studies have revealed that alterations in FF lipid composition are associated with follicular growth and oocyte development, thereby affecting IVF outcomes [ 25 – 30 ]. Some studies have also sought to identify lipid metabolites in the FF as predictive markers of ovarian stimulation and follicular development [ 31 – 32 ].\nHowever, few studies have investigated the composition of BMI-related lipid metabolites in the FF [ 12 , 22 , 26 , 33 – 35 ]. Triacylglycerols (TAG) and free fatty acids (FA) have been the focus of most studies on lipid metabolites [ 12 , 22 , 25 , 26 , 34 , 35 ]. While one study revealed no significant change in FF metabolic composition according to BMI, many others have demonstrated a positive correlation between maternal BMI and TAG/FA accumulation, which impairs oocyte development [ 12 , 22 , 25 , 31 ]. Additionally, animal  in vitro  maturation studies using lipid supplementation indicate that lipid metabolism with TAG and FA deposition influences oocyte maturation and development [ 36 – 38 ]. However, data on its effects on human oocyte maturation are limited.\nTherefore, a comprehensive lipidomics profiling of the FF was conducted to identify changes in metabolites and their effects on oocyte development and embryological outcomes in Korean women with infertility and obesity, defined as a BMI ≥ 25 kg/m 2  by the Korean Society for the Study of Obesity (KSSO) [ 39 ].\n\nThis was a single-center prospective cohort study. A total of 68 women without metabolic diseases (such as hyperlipidemia, hypertension, and diabetes mellitus) who underwent IVF/intracytoplasmic sperm injection (ICSI)-embryo transfer between February 2023 and September 2023 were included. The duration of infertility was defined as the period from the initial attempt at conception to the confirmation of clinical pregnancy as reported by the patient through self-examination. Women were divided into two BMI groups according to the KSSO definition. Group A (n = 28) was defined as the obese group with a BMI ≥ 25 kg/m 2 , whereas Group B (n = 40) was defined as the non-obese group with a BMI < 25 kg/m 2 . Transvaginal ultrasound-guided aspiration was used to collect FF from the antral follicles >15 mm during oocyte retrieval.\nA stereomicroscope and glass Pasteur pipette were used to retrieve the COC. Following oocyte retrieval, the FF was examined macroscopically. Follicular aspirates exhibiting severe viscosity, lack of clarity, or contamination with endometriotic cysts or the flushing medium were discarded. Only the uncontaminated FF samples were included in the analysis. All samples were preserved at 4 °C and transported to the laboratory on melting ice. This study was approved by the Institutional Review Board of CHA Gangnam Medical Center (IRB approval number: 2022-09-002). Written informed consent was obtained from all the patients.\nAll patients underwent COH with gonadotropin-releasing hormone (GnRH) agonists or antagonists for pituitary suppression. Stimulation was personalized based on age, ovarian reserve test results, and previous ovarian responses to gonadotropins during stimulation cycles. Ovulation was induced using 250–500 μg of recombinant human chorionic gonadotropin (hCG) (Ovidrel®; Serono, Modugno, Italy) and 0.1–0.2 mg of GnRH agonist (Decapeptyl®; Ferring, Sweden) when at least three follicles with a diameter of at least 17 mm or at least two follicles with a diameter of at least 18 mm were observed in both groups. Oocytes were retrieved 34–36 h after hCG and GnRH agonist administration.\nEmbryological outcomes were assessed as follows: Mature oocytes (metaphase II [MII] oocytes) were defined as those with the first polar body and were subsequently used for ICSI. The oocyte maturation rate was defined as the ratio of MII oocytes to the total number of oocytes retrieved. The presence of two pronuclei and a second polar body 16–18 h after insemination confirmed normal fertilization. The normal fertilization rate was calculated by dividing the number of normally fertilized oocytes by the total number of retrieved oocytes. Total cleavage (CL), morula (MO), and blastocyst (BL) embryo formation rates were determined by dividing the number of embryos at each stage by the number of normally fertilized oocytes. Usable embryos were defined as those available for fresh embryo transfer, pre-implantation genetic testing, or vitrification.\nThe liquid chromatography-mass spectrometry (LC-MS) grade solvents (isopropanol, methanol, and water), ammonium acetate, butylated hydroxytoluene, chloroform, and methyl  tert -butyl ether were procured from Sigma-Aldrich (St. Louis, MO, USA). The internal standards were procured from Avanti Polar Lipids (Alabaster, AL, USA) and Sigma-Aldrich (St. Louis, MO, USA) ( Table 1 ).\nThis table presents the details of the internal standards from Avanti SPLASH Lipid MIX. Internal standards, crucial for ensuring the reproducibility of the analyses, were prepared at a final concentration achieved through a 100-fold dilution, as described above.\nAbbreviations: conc., concentration; PC, plasmenyl phosphatidylcholine; LPC, lysophosphatidylcholine; PE, phosphatidylethanolamine; LPE, lysophosphatidylethanolamine; CE, cholesteryl ester; SM, sphingomyelin; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol; GalCer, galactosylceramides.\nThe Matyash method (with minor modifications) was used for all lipid extractions [ 40 ]. In brief, methanol (300 μL) containing 0.1% butylated hydroxytoluene and methyl  tert -butyl ether (1 mL) was added to the FF (100 μL). After shaking for 1 h at room temperature, 250 μL of water was added, and the mixture vortexed for 10 min. Centrifugation was performed at 14,000 × g (4 °C, 15 min) for phase separation. The upper (220 μL) and lower (110 μL) phases were combined for analysis, and the solvent was evaporated. The sample was then reconstituted in 90 μL of methanol:chloroform (9:1, v/v) solvent with an internal standard mixture (10 μL) ( Fig 1 ). This mixture contained PC 33:1-d7, LPC 18:1-d7, PE 33:1-d7, LPE 18:1-d7, CE 18:1-d7, SM 36:2-d9, MAG 18:1-d7, DAG 33:1-d7, TAG 48:1-d7, cholesterol-d7, ceramide 42:1-d7, AC 2:0-d3, and galactosylceramides 30:1.\nLC-MS/MS (Shimadzu LCMS 8060 system, Shimadzu, Mass Spectrometry Based Convergence Research Institute, Kyungpook National University, Kyoto, Japan) was used to analyze all samples. Kinetex C18 column (100 × 2.1 mm, 2.6 μm particle size, Phenomenex, Torrance, CA, USA) was used to separate them. Mobile phases A and B consisted of 10 mM ammonium acetate in water/methanol (1:9, v/v) and 10 mM ammonium acetate in methanol/isopropanol (1:1, v/v), respectively. The gradient elution conditions were: 30% B (0 min), 95% B (15 min), 95% B (20 min), and 30% B (25 min). The sample injection volume was 1 μL, and the flow rate was maintained at 0.2 mL/min. The mass operating conditions were as follows: desolvation temperature, 250 °C; heat block temperature, 400 °C; spray voltage, 4 kV; drying gas (nitrogen) flow rate, 10 L/min; collision gas, argon; nebulizing gas (nitrogen) flow rate, 3 L/min; collision gas pressure, 230 kPa; and detector voltage, 1.82 kV. Selected reactions were monitored. Three samples were randomly selected from each group for the preliminary experiment, yielding 230 lipid species. These detected lipids were then analyzed. In the final analysis, 159 of 230 lipids ( Table 2  and  S1 - S5 Tables ) in the FF samples were quantified after validating the assay by confirming the presence of lipid species with a coefficient of variation <30% of the quality control (QC) sample.\nThe data for all detected peaks, including the peak areas and retention times, were exported to an Excel file for lipidomic analysis. The QC samples were prepared by mixing equal amounts of lipid extracts from all samples. Lipidomics data were analyzed using the Student’s t-test, Welch’s t-test, or Wilcoxon rank-sum test based on the underlying assumptions of the parametric tests, including normality and equality of variance. The analyses were performed using the stats R package. Principal component analysis (PCA) was performed using the prcomp function in the stats R package. Correlation analyses were performed using the rcorr function in the HMISC R package. The p-values were adjusted for multiple comparisons using the Benjamini-Hochberg method with the p.adjust function from the stats R package. PCA and scatter plots were generated using the ggplot2 package in R.\nInter-group differences in clinical outcomes were assessed using the Student’s t-test, Welch’s t-test, or Wilcoxon rank-sum test for continuous variables, depending on the underlying assumptions of the parametric tests. Categorical variables are presented as percentages, and differences in these variables were analyzed using the Chi-squared test or Fisher’s exact test. Due to unequal sample sizes, analysis of covariance or Quade’s analysis of covariance was used to evaluate the differences between the BMI groups and embryological outcomes of IVF/ICSI, adjusting for potential confounders. Age and anti-Müllerian hormone (AMH) levels were selected as covariates based on clinical knowledge. P-values < 0.05 were considered statistically significant. All analyses were performed using R software version 4.4.1.\n\nThe clinical characteristics of the 68 patients included in this study are presented in  Table 3 . Group A (obese group, BMI ≥ 25 kg/m 2 ) comprised 41.2% (n = 28) of the participants, whereas Group B (non-obese group, BMI < 25 kg/m 2 ) comprised 58.8% (n = 40). The mean BMIs for the two groups were significantly different (Group A: 27.78 ± 2.12 kg/m 2 ; Group B:22.00 ± 2.37 kg/m 2 ;  p  < 0.001). The mean total serum cholesterol levels were significantly different between groups (Group A: 213.78 ± 36.64 mg/dL; Group B: 195.24 ± 0.78 mg/dL;  p  = 0.031). Additionally, the total cholesterol levels were positively correlated with the BMI ( p  = 0.002); a unit-increase in BMI corresponded to an estimated increase of 3.601 mg/dL in the serum cholesterol levels. Other variables, including age, cause of infertility, antral follicle count, basal follicle-stimulating hormone levels, AMH levels, infertility duration, and number of previous IVF attempts, were not significantly different between the groups. Other cycle variables, including stimulation protocol, total gonadotropin dose, duration of stimulation, estradiol level on the triggering day, type of trigger, and fertilization type, did not show significant differences between the groups ( Table 4 ).\nBMI, body mass index; PCOS, polycystic ovary syndrome; AFC, antral follicle count; AMH, anti- Müllerian hormone; FSH, follicle-stimulating hormone; IVF,  in vitro  fertilization; n, number of cycles; NS, not significant ( p  > 0.05). Values are presented as mean ± standard deviation\nn, number of cycles; BMI, body mass index; GnRH, gonadotropin-releasing hormone; Ovi, oviderel; Deca, decapeptyl; IVF,  in vitro  fertilization; ICSI, intracytoplasmic sperm injection. Values are presented as mean ± standard deviation or as number (%).\nA total of 159 of the 230 lipids ( Table 2  and Additional File 1,  S1– S5 Tables ) in the FF samples were quantified. The assay was validated by confirming that lipid species with coefficient of variation <30% in the QC sample exceeded 70% (83.0%) of the total lipid species [ 41 ]. Significant differences were observed between the two groups in all neutral lipid compositions ( Figs 2  and  3 ). Group A exhibited markedly higher concentrations of TAG than Group B (Group A: 132,443.3 ± 71,011.6 pmol/mL; Group B: 92,298.1 ± 41,084.8 pmol/mL;  p  = 0.0102;  Fig 2 ). Similarly, DAG levels were also elevated in Group A relative to Group B (Group A: 1,788.4 ± 903.0 pmol/mL; Group B: 1,198.0 ± 636.9 pmol/mL;  p  = 0.0014;  Fig 2 ). However, MAG levels (16:0) demonstrated a negative correlation with the BMI (Group A: 115,531.2 ± 16,058.7 pmol/mL; Group B = 126,500.0 ± 17,281.2 pmol/mL;  p =  0.0149;  Fig 3A ).\nThe bar graphs show the differences in lipid concentrations between the BMI groups. The lipid concentration (pmol/mL) was normalized to the volume. Different letters indicate significant differences compared with the control group [(*)  p  < 0.05, (**)  p  < 0.01], as determined using the t-test. Data are shown as mean ± standard deviation (n = 28 and n = 40). BMI, body mass index; LPC, Lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol; SM, sphingomyelin; CER, ceramide; CE, cholesteryl ester; AC, acylcarnitine; Group A, obese group; Group B, non-obese group.\nThe bar graphs show the lipid subgroup concentration differences between the BMI groups and (A) MAG, (B) DAG, and (C) TAG. The lipid concentration (pmol/mL) was normalized to the volume. Different letters indicate significant differences compared with the control group [(*)  p  < 0.05, (**)  p  < 0.01], as determined by the t-test. The data shown as mean ± standard deviation (n = 28 and n = 40). BMI, body mass index; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol.\nAdditionally, a notable difference was observed in the composition of neutral lipids between groups. In Group A, the compositions of TAG and DAG were higher at 53.02% and 0.72%, respectively, compared to Group B, which had compositions of 41.19% and 0.54%, respectively. Conversely, Group A exhibited lower MAG content (46.26%) than Group B (57.27%).\nFurther analysis was conducted on the DAG lipid chains, covering five DAGs (32:2, 32:1, 34:0, 36:5, and 36:1), all showing statistical significance, with mean concentrations positively correlated with the groups ( Fig 3B ). Additionally, the analysis of 37 TAGs revealed significant differences in TAGs 48:0, 50:4, 50:3, 50:2, 50:1, 50:0, 52:5, 54:4, 52:3, 52:2, 52:1, 54:6, 54:5, 54:4, 54:3, 54:2, and 56:7 ( Fig 3C ).\nAdditionally, total AC levels were higher in group A than in group B (Group A: 4878.1 ± 1179.3 pmol/mL; Group B: 4302.1 ± 1216.0;  p  = 0.0222;  Fig 2 ). Chain analysis revealed significant differences in C2:0, C3:0, C16:0, C18:0, and C18:1 levels, all of which were higher in Group A than in Group B ( Fig 4 ).\nThese bar graphs show the concentration differences between the BMI groups and the AC subgroup. The lipid concentration (pmol/mL) was normalized to the volume. Different letters indicate significant differences compared with the control group [(*)  p  < 0.05, (**)  p  < 0.01], as determined by the t-test. The data shown as mean ± standard deviation (n = 28 and n = 40). BMI, body mass index; AC, acylcarnitine.\nOf the phospholipid family, only plasmenyl PC demonstrated a statistically significant inverse relationship with the BMI (Group A: 1,6093.3 ± 5323.7 pmol/mL; Group B: 1,8121.9 ± 4797.2 pmol/mL;  p  = 0.0423;  Fig 2 ). Further analysis of plasmenyl PC chains revealed that plasmenyl 34:0, 36:2, 40:7, and 40:4 showed significantly higher levels in Group B. No significant differences were observed between the groups in other lipids, such as sphingolipids (sphingomyelin and ceramide) or sterol lipids (cholesterol and cholesteryl ester) ( Fig 2 ).\nAdjusted  p -value analysis revealed that, among the total lipids, only DAG showed a significant difference between groups. Among the total lipid chains, only AC 16:0 differed significantly between groups (adjusted p < 0.05).\nThe lipid and lipid chain concentration data were not clearly separated between the obese and non-obese groups in the PCA ( Figs 5A  and  5B ). When analyzing only the lipids and lipid chains that showed a significant difference in abundance between the groups ( p  < 0.05), some differences were observed. The variance explained by the first principal component increased significantly from 36.7% to 38.9% and from 26.8% to 41.0% for lipids and lipid chains, respectively, indicating that these discriminatory lipids or lipid chains could help distinguish between the groups ( Figs 5C  and  5D ).\nThe PCA plots show that the distributions of (A) all lipids, (B) all lipid chains, (C) lipids, and (D) lipid chains were significantly different between the two groups. The light green and red areas represent the 95% confidence intervals for each group. PCA, principal component analysis.\nCorrelation analysis revealed a significant positive correlation between BMI and TAG, DAG, and AC levels (adjusted  p  < 0.05;  Fig 6 ). Further analysis of AC chains showed that AC 3:0, 16:0, 16:1, 18:0, and 18:1 levels were significantly positively associated with the BMI (adjusted  p  = 0.014, 0.006, 0.019, 0.029, and 0.014, respectively;  Fig 7 ).\nThese scatter plots show a positive correlation between the BMI and (A) TAG, (B) DAG, and (C) AC levels, respectively. The red line represents the linear regression fit of each data point and the gray area indicates the 95% confidence interval of the regression fit. The correlation coefficient (r) was calculated using Spearman’s correlation method. BMI, body mass index; TAG, triacylglycerol; DAG, diacylglycerol; AC, acylcarnitine.\nScatter plots show a positive correlation between the BMI and (A) AC 3:0, (B) AC 16:0, (C) AC 16:1, (D) AC 18:0, and (E) AC 18:1. The red line represents the linear regression fit of each data point and the gray area indicates the 95% confidence interval of the regression fit. The correlation coefficient (r) was calculated using Spearman’s correlation method. BMI, body mass index; AC, acylcarnitine.\nAfter adjusting for maternal age and AMH, which had the most significant impact on embryological outcomes, notable differences were observed in the numbers of fertilized oocytes, CL-stage embryos, and MO-stage embryos between Groups A and B. The total number of oocytes retrieved during the COH cycle was comparable between groups. However, in comparison to Group B, Group A had significantly fewer fertilized oocytes (Group A: 5.07 ± 4.16; Group B: 6.65 ± 4.61;  p  = 0.043), as well as fewer CL-stage (Group A: 4.86 ± 4.26; Group B: 6.63 ± 4.61;  p  = 0.016) and MO-stage (Group A: 4.00 ± 4.51; Group B: 6.05 ± 5.14;  p  = 0.024) embryos. Nevertheless, Group A exhibited lower values across various embryological outcomes, including the number of mature oocytes retrieved, oocyte maturation rate, fertilization rate, CL-embryo formation rate, MO-embryo formation rate, number of total BL-stage embryos, BL formation rate, number of usable embryos, and usable embryo rate; however, these differences were not statistically significant ( Table 5 ).\nData are presented either as mean ± standard deviation or as percentages.\nAbbreviations: IVF,  in vitro  fertilization; BMI, body mass index; AMH, anti-Müllerian hormone.\n\nLipid metabolic pathways, including the TAG breakdown, FA oxidation, and cholesterol uptake pathways, are active within the COC. The lipid and FA compositions of the FF vary with the developmental stage of the ovarian follicle, reflecting differences in lipid function [ 15 , 27 ]. Because oocytes have low glycolytic activity, they primarily depend on internal lipid storage within the COC and external sources such as FAs and amino acids from the FF for energy [ 15 , 22 , 26 ]. This metabolically quiescent state continues until the early CL stage due to limited glycolytic activity [ 42 ]. Recent proteomics and transcriptomics studies have highlighted the essential role of lipid metabolism in folliculogenesis and oocyte maturation [ 42 – 44 ]. Lipid metabolism influences chromatin dynamics and gene expression, affecting both nuclear and cytoplasmic maturation of oocytes and early embryonic development [ 43 ]. As COH promotes the development of additional follicles and maturation of more oocytes, lipid metabolism becomes increasingly crucial.\nHere, we report that neutral lipids, which are the primary sources of lipid metabolism, exhibited the most significant differences between the obese and non-obese groups. Consistent with other studies, the TAG levels were markedly higher in the obese group than in the non-obese group, indicating a significant positive correlation with the BMI [ 12 , 22 , 25 , 26 , 34 , 35 ]. Additionally, we observed significant differences in the numbers of fertilized oocytes, CL-stage embryos, and MO-stage embryos between the groups. This aligns with existing studies indicating that elevated triglyceride (TG) levels in the FF are associated with oocyte CL failure and reduced embryo viability [ 12 , 22 , 31 , 45 ].\nIn addition to elevated TAG levels, our analysis revealed that the obese group exhibited higher DAG levels, suggesting a statistically significant positive correlation with the BMI. In contrast, the obese group exhibited lower MAG levels than the non-obese group.\nLipolysis in the COC involves the action of lipases, which are likely to be regulated during maturation. Lipolysis begins with the action of adipose TG lipase, which hydrolyzes TAG to DAG and FA. Subsequently, a hormone-sensitive lipase breaks down DAG into MAG, which is ultimately converted into FA and glycerol by MAG lipase [ 46 ]. Our results suggest that the initial steps of lipolysis in the FF are less effective in the obese group, as indicated by the accumulation of DAG, an intermediate metabolite, and reduced levels of MAG, the final metabolite of lipolysis. Although the mechanisms linking obesity and ineffective lipolysis within the COC are not well-established, a study on adipocytes showed decreased catecholamine-stimulated lipolysis and an antilipolytic effect of insulin in obesity [ 47 ].\nFurthermore, incomplete lipolysis leads to the accumulation of DAG, a critical signaling molecule, during fertilization and early embryonic development. After sperm and oocyte fusion, DAG is generated by sperm-specific phospholipase C zeta hydrolyzing phosphatidylinositol 4,5-bisphosphate [ 48 ]. DAG then activates protein kinase C (PKC), which regulates meiosis resumption, cytoskeletal dynamics, and the mitogen-activated protein kinase pathway, which are essential for oocyte maturation, fertilization, and early embryonic development [ 49 – 51 ].\nHowever, research on mouse COC revealed that high DAG concentrations eventually reduce fertilization, as excessive DAG in phospholipase C zeta-injected eggs can trigger PKC-mediated Ca 2+  influx, leading to Ca 2+  overload and disrupted homeostasis [ 51 ]. Microinjection of DAG into oocytes also results in developmental arrest at the 4- to 68-cell stage [ 52 ]. Additionally, prolonged DAG activation in T cells downregulates PKC isoforms [ 53 – 55 ]. Studies in human liver and muscle tissues have indicated that elevated DAG levels activate PKC, disrupt insulin signaling, and contribute to insulin resistance and lipotoxicity [ 56 – 58 ]. Although no study has specifically examined the effects of DAG on human oocytes, our findings suggest that elevated DAG levels may contribute to poor fertilization and embryonic outcomes.\nAC acts as the transportation site for FAs across the mitochondrial membrane and undergoes β-oxidation, which is a significant energy-producing process [ 55 ]. Given that oocytes and early embryos exhibit low glycolytic activity, β-oxidation is crucial during these stages. The accumulation of ACs in the obesity group indicates incomplete β-oxidation and, by extension, an inefficient FA oxidation process. This inefficiency can lead to decreased adenosine triphosphate levels, which may disrupt meiotic spindle formation and lead to failure of chromosomal segregation, maturation, and fertilization [ 59 ]. These disruptions are characterized by a lower number of fertilized oocytes and poor early embryological outcomes. Furthermore, long-chain ACs are correlated with gonadotropin-induced T levels, resulting in hormonal imbalances [ 24 ]. Additionally, a metabolomics study revealed that elevated plasma levels of medium- and long-chain ACs are associated with an increased risk of diabetic cardiomyopathy, which exacerbates myocardial lipotoxicity [ 60 ]. Thus, our detailed analysis of individual AC chains provides valuable insights, suggesting that the accumulation of ACs may be detrimental to embryological outcomes.\nIn this study, we utilized a large-scale untargeted lipidomic approach to comprehensively identify lipidomic profiles and analyze a diverse range of lipid classes and subtypes. A few human studies have explored the relationship between BMI, FF lipidomes, and embryological outcomes. Although the dynamics of lipid metabolism during oocyte maturation, fertilization, and early embryonic development in humans remain unclear, our findings highlight significant differences in the composition of follicular fluid lipids and their influence on embryological outcomes. However, this study has several limitations.\nWhile we excluded patients with underlying metabolic diseases, we included three individuals with endometriosis and six with polycystic ovary syndrome, which may influence the local FF microenvironment. However, the number of patients with these conditions was small. Additionally, only metabolically healthy patients with polycystic ovary syndrome and those with mild endometriosis (lesions ≤ 1.5 cm) were included in our analysis. Few studies have suggested a relationship between FF lipid changes, age, and ovarian reserve [ 61 , 62 ]. However, the lack of significant differences in the mean AMH levels or age between the obese and non-obese groups suggests that age possibly had minimal impact on our findings. Since we focused on patients without hyperlipidemia, we only measured total serum cholesterol levels. Given that the composition of FF metabolites originates from the blood and COC, additional lipidomic analyses, including LDL, HDL, and TGs, would further enhance our understanding of how obesity affects the FF lipidome. The small sample size is another limitation, and it is challenging to determine whether the observed results are a cause or an effect. Consequently, studies with larger sample sizes are warranted to validate our findings, and further mechanistic studies are required to elucidate the underlying pathways. In addition, multicenter studies involving diverse populations are essential to confirm the generalizability of our findings across different clinical settings.\n\nThis is the first large-scale lipidomic study involving the FF to identify differences in metabolic profiles in the ovarian microenvironment associated with obesity in Korean women with infertility. We observed significant differences in the number of fertilized oocytes, CL-stage embryos, and MO-stage embryos, indicating altered embryonic development in the obese group. Analysis of the FF lipid composition provides valuable insights into the metabolic state and microenvironment of the COC. The accumulation of TAGs and DAGs, coupled with lower levels of MAGs and higher levels of ACs in the obese group, indicated inefficient lipid metabolism with insufficient energy production and potential lipotoxicity. This lipid imbalance may compromise early embryological outcomes in patients with obesity. Our results provide crucial insights into the importance of balanced lipid metabolism under conditions of increased energy demand during early embryonic development. This study provides a deeper understanding of the pathophysiology of lipid metabolism and obesity during early embryonic development. Mechanistic studies with larger sample sizes are needed to understand obesity-associated lipid metabolism and develop targeted interventions to improve fertility outcomes in women with obesity. Moreover, multicenter studies are necessary to enhance the external validity of our results and ensure their applicability to broader patient populations.\n\nSRM, selected reaction monitoring; LC, liquid chromatography; MS, mass spectrometry; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine\n(DOCX)\nSRM, selected reaction monitoring; LC, liquid chromatography; MS, mass spectrometry; MAG, monoacylglycerol; DAG, diacylglycerol; TAG, triacylglycerol.\n(DOCX)\nSRM, selected reaction monitoring; LC, liquid chromatography; MS, mass spectrometry; SM, sphingomyelin; CER, ceramide.\n(DOCX)\nSRM, selected reaction monitoring; LC, liquid chromatography; MS, mass spectrometry; CE, cholesteryl ester.\n(DOCX)\nSRM, selected reaction monitoring; LC, liquid chromatography; MS, mass spectrometry.\n(DOCX)","source_license":"CC-BY-4.0","license_restricted":false}